Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Home & Anonymous Lab Testing of Gray-Market Compounds

Reagent kits and anonymous analytical services (Janoshik and similar), what they can and cannot tell you

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (consumer/community testing tools, not a regulatory program)

Reference only. Not medical advice.

What can go wrong

The harm-reduction value is real but bounded. Over-reliance on a clean content test can create false confidence about sterility and about future batches. Sending samples also does not undo an already-injected product, and reagent kits in particular give only a coarse read that can miss substitution or dose problems.

This is something to take to a clinician. The Atlas can tell you what is known about home & anonymous lab testing of gray-market compounds in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Because gray-market product is structurally unverified, a community-testing ecosystem has grown up around it: color-change reagent kits that give a rough presence/absence read, and anonymous quantitative lab services, Janoshik Analytical (Czech Republic) being the most cited, that run HPLC/mass-spec on user-submitted samples and publish results. These services have repeatedly exposed under-dosed and substituted UGL and SARM product (e.g., publicly documented vials testing 25-40% below label). This entry explains what such testing genuinely establishes and, importantly, what it does not: it cannot confirm sterility, and reagent kits cannot quantify dose.

Testing can catch an under-dose or a wrong compound. It cannot make a vial sterile.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Checking whether a product contains the labeled compound
  • Estimating dose accuracy of an injectable or oral

How it is supposed to work

A reagent kit reacts with a compound class to give a color, offering a crude presence/identity signal but no quantity. An anonymous analytical lab dissolves and runs the sample on chromatography/mass spectrometry, returning an actual concentration and identity. Reputable services publish anonymized results, creating a partial feedback loop that has surfaced systematically under-dosed labs. The reputation of the most-cited services emerged from community verification rather than the services' own marketing.

The sterility blind spot

The single most important limitation: a quantitative assay tells you what and how much is in the vial, but standard content testing does not certify sterility or absence of bacterial endotoxin. A perfectly dosed vial can still cause an injection-site abscess or systemic infection. Testing also only speaks to the specific sample submitted, the next batch, or even the next vial of the same batch, is not covered.

Safety in detail

  • Content testing does not certify sterility or endotoxin
  • Results apply only to the submitted sample, not future batches
  • Reagent kits cannot quantify dose
  • False confidence is itself a documented risk

What people get wrong

  • Often said'A clean Janoshik test means the vial is safe to inject'

    ActuallyIt means the content matched, not that the vial is sterile or endotoxin-free, and not that the next batch will match.

  • Often said'A reagent kit confirms my dose'

    ActuallyReagent kits give presence/identity color reads only; they cannot quantify milligrams.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

What we do not know

  • Can anonymous content-testing programs be paired with sterility/endotoxin screening to close the biggest blind spot?
  • Does published testing measurably shift the market toward accurately dosed product over time?

At a glance

Reagent kits
Color-change; rough presence/identity only, not dose
Quantitative labs
HPLC/mass-spec on submitted samples (e.g., Janoshik)
What testing catches
Under-dosing, over-dosing, wrong-compound substitution
What testing misses
Sterility, endotoxin, batch-to-batch drift after the tested lot

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Home & Anonymous Lab Testing of Gray-Market Compounds. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Publicly documented Janoshik quantitative resultsongoing

    Multiple UGL and SARM products found substantially under-dosed or containing a different compound than labeled

  • Community AAS testing harm-reduction pilot2024

    Demonstrated feasibility of user-submitted chemical analysis and community results dissemination as a harm-reduction tool